Many patients and even some healthcare professionals struggle to navigate complex medicine documentation — what if the leaflet inside the box doesn’t explain clearly why or how to use a medicine? Without clear, patient-friendly guidance, misunderstanding dosage or ignoring important safety warnings can lead to serious risks. That’s why a well-written SmPC and corresponding Patient Information Leaflet are essential: they ensure that both prescribers and patients receive accurate, understandable and up-to-date information, enabling safe and effective use of medicines.

What does a SmPC actually contain and why is its structure important?

The Summary of Product Characteristics(SmPC) is a cornerstone document in regulatory medicine — it gathers all the scientifically validated, authorised information about a medicinal product: indications, dosing, contraindications, pharmacological properties, safety profile, use in special populations (children, elderly, renal/hepatic impairment) and more.

In the context of medical writing services, preparing an SmPC requires expertise to translate complex clinical and nonclinical data, pharmacology and safety studies into a coherent, legally compliant document. A well-structured SmPC ensures clarity and consistency for healthcare professionals: each section must follow a predefined template (as per regulatory guidelines, for example EMA’s Quality Review of Documents or QRD) to avoid ambiguity.

Because the SmPC forms the regulatory backbone of a medicine’s information, its structure is not optional — misplacement or omission of data (e.g., dosage for special populations, contraindications, adverse effects) can lead to misuse or regulatory non-compliance. Thus, the integrity of the SmPC’s structure is foundational for correct prescribing, safe use and downstream documents like the patient leaflet.

Who is the intended audience for the SmPC versus the patient information leaflet, and why does it matter?

The primary audience for the SmPC are healthcare professionals — doctors, pharmacists, nurses — who need detailed, technical information to prescribe or dispense the medicine safely and effectively. In contrast, the Patient Information Leaflet (PIL) (or package leaflet) is written for patients or lay users: its language, style and presentation must be accessible, understandable, and focused on practical use (how to take the medicine, what to watch out for, common side effects etc.). The difference in audience matters because misunderstanding or mis-interpretation can lead to medication errors. For instance, a patient may be overwhelmed or confused by technical pharmacokinetic data that belongs in the SmPC; conversely, a doctor needs those scientific details to make informed therapeutic decisions.

At Billev Pharma East we recognise this distinction — our regulatory writing services ensure that the SmPC is sufficiently technical and compliant for professionals, while PILs derived from it are tailored to patients’ needs: clear, concise, and easy to follow. A correct match between audience and document type preserves both safety and usability — patients get what they need to take medicine properly, and professionals get the full picture to guide therapy.

How does information from the SmPC flow into the patient information leaflet (PIL)?

The SmPC serves as the authoritative source for all medicinal product data — when preparing the Patient Information Leaflet (PIL), authors typically extract and adapt relevant content from the SmPC. According to regulatory guidance, the PIL should reflect the approved indications, dosing instructions, contraindications, warnings, potential side effects and storage instructions. However, the transformation is not a mere copy-paste: the content must be rewritten in a non-technical, patient-friendly language. Complex medical terminology or detailed pharmacological mechanisms must be simplified, while practical instructions (when to take the medicine, what to do if a dose is missed, common side effects, emergency warnings) should be prioritised. The PIL must be understandable for laypersons with no medical background.This flow — from comprehensive regulatory document (SmPC) to simplified patient leaflet (PIL) — ensures consistency across official documentation and supports both safe prescribing and correct usage by patients. Any update in the SmPC (e.g., new safety data) should trigger a corresponding PIL revision, to keep patient-facing information up to date.

Thus, the SmPC → PIL pathway is critical for bridging regulatory detail and user-friendly communication, safeguarding both clinical rigour and patient comprehension.

How is content selected from the SmPC for use in the PIL?

When preparing the Patient Information Leaflet (PIL), only certain parts of the Summary of Product Characteristics (SmPC) are transferred — specifically those relevant to patients: what the medicine is for, how to take it, common/serious side-effects, warnings/precautions, and practical storage or use instructions. Regulatory guidance requires that the PIL be “clear and understandable” and written in plain language, adapted to a lay audience.

What regulatory requirements govern the SmPC and PIL — and how do they differ?

In the European Union, the use of SmPC and Patient Information Leaflet (PIL) is regulated under legislation such as Directive 2001/83/EC (and related regulation 726/2004) — these establish that any authorised medicine must include a summary of product characteristics plus a package leaflet as part of the product information. The layout, content and wording of both SmPC and PIL must comply with the template defined by the European Medicines Agency (EMA), via the so-called QRD (Quality Review of Documents) template, which dictates standard headings, phrasing and order. While the SmPC must contain detailed scientific, pharmacological, safety and usage data for professionals, the PIL must meet readability requirements: language must be clear, non-technical, and suitable for patients. Folding in readability testing or plain-language criteria (especially for translation to national languages) is often required. Moreover — because the regulatory authority (e.g., EMA or national competent agency) approves both the SmPC and the PIL — any change (for example new safety signal, updated dosage, new contraindications) typically triggers a formal variation procedure, meaning both documents must be updated in tandem to remain compliant.

Why might safety updates in the SmPC trigger changes in the patient information leaflet?

Medicines’ safety profiles can evolve over time: post-marketing surveillance, new clinical data or adverse reaction reports sometimes reveal previously unknown risks or updated frequency/severity of side effects. Since the SmPC is the reference document for scientific and safety information, any such new data must be reflected there. Because the Patient Information Leaflet (PIL) is derived from the SmPC, a safety update in the SmPC should prompt a revision in the PIL to ensure patients receive up-to-date information. This is essential for patient safety — for example, new contraindications, warnings, interactions or rare but serious adverse effects must be clearly communicated to users. Failing to update the PIL accordingly may lead to patients relying on outdated information, which could cause misuse, increased risk of harm, or under-reporting of adverse reactions. Thus, regulatory guidance requires that marketing-authorisation holders maintain both documents throughout the product lifecycle.

In short: safety updates in the SmPC are not just a matter for professionals — they have direct implications for patients, and trigger the need for updated, accurate patient-facing information.

Implications of SmPC changes for patient safety information

When post-marketing data reveal new safety signals — for example through pharmacovigilance reports, real-world evidence or updated clinical trial results — the authoritative document Summary of Product Characteristics (SmPC) must be revised to reflect the latest benefit–risk profile of the medicine. Because the Patient Information Leaflet (PIL) is derived from the SmPC, any safety-driven update in the SmPC should trigger a corresponding update of the PIL — ensuring that patients receive accurate, up-to-date information about indications, contraindications, adverse effects or precautions. Failing to synchronise PIL with SmPC can lead to outdated or incomplete patient guidance, which may jeopardize safe and effective use of the medicine. Therefore regulatory frameworks enforce that changes affecting safety or core product information prompt a formal variation submission, including updated PIL, to the competent authority.

In which situations does reading the SmPC make a difference in clinical practice compared to the PIL?

There are scenarios where the technical detail in the SmPC becomes crucial — for example, when prescribing for special populations (children, elderly, patients with organ impairment), performing dose adjustments, managing drug–drug interactions, or considering complex contraindications. The SmPC contains precise data on pharmacokinetics, pharmacodynamics, off-label populations, and special warnings that a PIL simply cannot capture. In contrast, the PIL is crafted for general patients, covering basic usage instructions, common warnings and side effects. It rarely includes the details needed for clinical decision-making. Therefore, in hospital settings, during prescription, or when a patient has comorbidities or uses multiple medicines, healthcare professionals rely on the SmPC’s comprehensive, approved data. For routine patient counselling or initial patient use, the PIL remains sufficient. This dual-document approach ensures that both professionals and patients have access to appropriate information according to their needs — optimising safety, efficacy, and compliance with regulatory and clinical best-practice.

What makes a PIL patient-friendly while the SmPC remains technical — and why both are needed?

The Patient Information Leaflet (PIL) is designed to be patient-friendly: it uses simple, non-technical language, clear formatting, bulleted instructions, short sentences and focuses on what the patient needs to know: why they take the medicine, how to take it, what to expect, what to watch out for (common side effects), and how to store it. This readability is essential to support correct use and adherence. On the other hand, the SmPC remains technical — it must include detailed clinical, pharmacological and regulatory information: mechanism of action, pharmacokinetics, dosing regimens, contraindications, interactions, special populations, adverse reactions with frequencies, etc. This level of detail is necessary for healthcare professionals to make informed prescribing decisions. Having both documents ensures a balance: the SmPC safeguards scientific rigour and regulatory compliance; the PIL ensures patient understanding and safe everyday use. Without the SmPC, clinicians lack the depth needed for responsible prescribing. Without the PIL, patients risk misunderstanding directions or missing important safety information.

Together, they form a complementary system — one technical, one accessible — that ensures safe, effective and patient-centred use of medicines.

Read also:

• Why are ICH GCP principles essential for creating compliant clinical documentation?
• What steps should you take to maintain medical accuracy in data-driven writing?
• What are common pitfalls when preparing “CTD module” submissions, and how can understanding the “CTD format” and “CTD modules” help avoid them?

Sources: 1 – European Medicines Agency. (n.d.). Product-information requirements: Summary of Product Characteristics, labelling and package leaflet, 2 – European Medicines Agency. (n.d.). Summary of product characteristics (SmPC), 3 – European Medicines Agency. (n.d.). How to prepare and review a Summary of Product Characteristics (SmPC), 4 – European Medicines Agency. (n.d.). SmPC: summary of product characteristics — What is it and what does it contain? Presentation, 5 – European Patients’ Academy on Therapeutic Innovation (EUPATI). (n.d.). Information on medicinal products — Summary of Product Characteristics and Package Leaflet, 6 – Docuvera. (n.d.). “What is the SmPC?” Summary of Product Characteristics (SmPC).

Image credits:

In-article images: 

Photo by Gustavo Fring by Pexels

Photo by Anna Shvets by Pexels

Photo by David Levinson by Pexels

Hero image: Photo by Vitaly Gariev by Unsplash